MoneyWorks4Me

Sun Pharma aims 'low-to-mid teens' growth in consolidated revenues in FY20

01 Aug 2019 Evaluate

Sun Pharmaceutical Industries is gradually ramping up its speciality business across global markets as it aims to clock ‘low-to-mid teens’ growth in consolidated revenues in the current fiscal (FY20). The company is focused at growing each of its business verticals faster than the market in which it operates.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Peers
Company Name CMP
Sun Pharma. Inds. 1801.00
Dr. Reddys Labs. 1209.15
Cipla 1343.00
Lupin 2035.00
Zydus Lifesciences 1160.00
View more..